A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy Meeting Abstract


Authors: Mato, A. R.; Schuster, S. J.; Lamanna, N.; Flinn, I.; Barrientos, J. C.; Kambhampati, S.; Cheson, B. D.; Barr, P. M.; Pagel, J. M.; Reeves, J. A.; Lansigan, F.; Pu, J. J.; Skarbnik, A. P.; Fonseca, G. A.; Dorsey, C.; Prak, E. L.; Paskalis, D.; Sportelli, P.; Miskin, H. P.; Brander, D. M.
Abstract Title: A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy
Meeting Title: 54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 15 Suppl.
Meeting Dates: 2018 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-05-20
Start Page: 407s
Language: English
ACCESSION: WOS:000442916002600
DOI: 10.1200/JCO.2018.36.15_suppl.7530
PROVIDER: wos
Notes: Meeting Abstract: 7530 -- Source: Wos
Altmetric Score
MSK Authors
  1. Anthony R Mato
    28 Mato
  2. Colleen Dorsey
    1 Dorsey